Antigens for cancer immunotherapy.

Progress in tumor immunology has not been translated to effective immunotherapies for cancer. Most of the current effort in basic and clinical research concentrates on generating effective immune responses against model or well characterized antigens, yet vaccines targeting defined antigens have been less clinically successful than those based on whole tumor cells or their extracts. This review considers characteristics of proteins that determine how effectively they might serve as targets of immune control, and how different sources of antigens have fared in clinical trials.

[1]  Bent K Jakobsen,et al.  Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors , 2006, The Journal of Immunology.

[2]  Danila Valmori,et al.  Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans , 2002, The Journal of experimental medicine.

[3]  K. Roemer,et al.  Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer , 2004, Cancer Research.

[4]  D. Tscharke,et al.  CD8+ T Cell Cross-Priming via Transfer of Proteasome Substrates , 2004, Science.

[5]  J. Wolchok,et al.  Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. , 2006, The Journal of clinical investigation.

[6]  D. Pardoll,et al.  Autoimmunity Epitope Results in Tumor Rejection But Not Activation of Low Avidity CTL Specific for a Self , 1998 .

[7]  L. Kwak,et al.  Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. , 2004, The Journal of clinical investigation.

[8]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[9]  F. Marincola,et al.  Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination , 2001, The Journal of Immunology.

[10]  S. Anderton.  Post-translational modifications of self antigens: implications for autoimmunity. , 2004, Current opinion in immunology.

[11]  Simon C Watkins,et al.  The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 , 2000, The Journal of Immunology.

[12]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[13]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[14]  L. Klein,et al.  Origin of regulatory T cells with known specificity for antigen , 2002, Nature Immunology.

[15]  小林 規俊.  FOXP3[+] regulatory T cells affect the development and progression of hepatocarcinogenesis , 2007 .

[16]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[17]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[18]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[19]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[20]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[21]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Mark S. Anderson,et al.  Projection of an Immunological Self Shadow Within the Thymus by the Aire Protein , 2002, Science.

[23]  J. Miller,et al.  CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[25]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[26]  V. Engelhard,et al.  Antigens derived from melanocyte differentiation proteins: self‐tolerance, autoimmunity, and use for cancer immunotherapy , 2002, Immunological reviews.

[27]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[28]  E. Davila,et al.  Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. , 2001, Journal of immunotherapy.

[29]  E. Gilboa,et al.  Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. , 2005, Cancer research.

[30]  B. Seliger,et al.  Loss of interferon‐γ inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post‐transcriptional as well as epigenetic regulation , 2008, The British journal of dermatology.

[31]  Philippa Marrack,et al.  T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells , 2000, The Journal of experimental medicine.

[32]  E. McCulloch,et al.  Mouse myeloma tumor stem cells: a primary cell culture assay. , 1971, Journal of the National Cancer Institute.

[33]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[34]  K. Ellem,et al.  Dendritic cell immunotherapy for stage IV melanoma , 2007, Melanoma research.

[35]  F. Sallusto,et al.  Dendritic cells up‐regulate immunoproteasomes and the proteasome regulator PA28 during maturation , 1999, European journal of immunology.

[36]  D. Schadendorf,et al.  Immunogenicity of Constitutively Active V599EBRaf , 2004, Cancer Research.

[37]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[38]  R. Dummer,et al.  Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution , 1998, Melanoma research.

[39]  S. Rosenberg,et al.  Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. , 2003, Cancer Research.

[40]  R. Offringa,et al.  High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. , 2000, Cancer research.

[41]  B. Brors,et al.  Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters , 2004, The Journal of experimental medicine.

[42]  H. Rammensee,et al.  HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. , 2001, The Journal of investigative dermatology.

[43]  J. Neefjes,et al.  The major substrates for TAP in vivo are derived from newly synthesized proteins , 2000, Nature.

[44]  F. Midgley,et al.  Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. , 2005, International immunology.

[45]  E. Gilboa,et al.  Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy , 2005, Clinical Cancer Research.

[46]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[47]  G. Ogg,et al.  High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo , 1998, The Journal of experimental medicine.

[48]  T. Schell,et al.  Accumulation of CD8+ T Cells in Advanced-Stage Tumors and Delay of Disease Progression following Secondary Immunization against an Immunorecessive Epitope1 , 2006, The Journal of Immunology.

[49]  D. Valmori,et al.  Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. , 2006, Cancer research.

[50]  K. Black,et al.  Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality 1 , 2003, The Journal of Immunology.

[51]  B. Brodin,et al.  Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. , 2005, Cancer research.

[52]  S. Rosenberg,et al.  Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. , 1999, Journal of immunotherapy.

[53]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[54]  M. van den Broek,et al.  Cross-Presentation of the Long-Lived Lymphocytic Choriomeningitis Virus Nucleoprotein Does Not Require Neosynthesis and Is Enhanced via Heat Shock Proteins1 , 2005, The Journal of Immunology.

[55]  F. Rodríguez,et al.  Immunodominance in Virus-Induced CD8+ T-Cell Responses Is Dramatically Modified by DNA Immunization and Is Regulated by Gamma Interferon , 2002, Journal of Virology.

[56]  E. Shevach,et al.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.

[57]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[58]  M. Herlyn,et al.  Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status , 2008, Journal of Cellular Physiology.

[59]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  N. Brouwenstijn,et al.  Antigen Bias in T Cell Cross-Priming , 2004, Science.

[61]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[62]  P. Coulie,et al.  Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.

[63]  A. Moffett,et al.  Immunology of placentation in eutherian mammals , 2006, Nature Reviews Immunology.

[64]  Zang Ai-hua,et al.  Stem Cells,Cancer and Cancer Stem Cells , 2005 .

[65]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[66]  Helen Y Wang,et al.  Regulatory T cells and cancer. , 2007, Current opinion in immunology.

[67]  F. Brasseur,et al.  A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.

[68]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[69]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[70]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[71]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[72]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  H. Rammensee,et al.  Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas , 2006, Clinical Cancer Research.

[74]  A. Anichini,et al.  Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. , 1996, Journal of immunology.

[75]  C. Liu,et al.  Targeting tumor-associated macrophages as a novel strategy against breast cancer. , 2006, The Journal of clinical investigation.

[76]  B. Neyns,et al.  Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells1 , 2008, The Journal of Immunology.

[77]  Yan P. Yuan,et al.  Frameshift peptide‐derived T‐cell epitopes: A source of novel tumor‐specific antigens , 2001, International journal of cancer.

[78]  Yutaka Kawakami,et al.  Human tumor antigens recognized by T-cells , 1997, Immunologic research.

[79]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[80]  G. Nicolini,et al.  Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. , 2005, Cancer research.

[81]  C. Farina,et al.  Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.

[82]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[83]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[84]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Sporn.  The war on cancer , 1996, The Lancet.

[86]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Y. Ward,et al.  Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. , 2002, Cancer research.

[88]  V. Brusic,et al.  Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A. Simpson,et al.  MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. , 2007, Cancer research.

[90]  V. Crotzer,et al.  Autophagy and intracellular surveillance: Modulating MHC class II antigen presentation with stress , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.

[92]  T. Schell,et al.  Epitope Immunization against an Immunorecessive Progression following Secondary DiseaseAdvanced-Stage Tumors and Delay of T Cells in + Accumulation of CD 8 , 2006 .

[93]  E. Sercarz,et al.  How some T cells escape tolerance induction , 1989, Nature.

[94]  Clare L. Bennett,et al.  Deletional Self-Tolerance to a Melanocyte/Melanoma Antigen Derived from Tyrosinase Is Mediated by a Radio-Resistant Cell in Peripheral and Mesenteric Lymph Nodes1 , 2007, The Journal of Immunology.

[95]  C. Huber,et al.  Transporter (TAP)‐ and proteasome‐independent presentation of a melanoma‐associated tyrosinase epitope , 2000, International journal of cancer.

[96]  H. Ananthaswamy,et al.  The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[98]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[99]  D. Schadendorf,et al.  High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma , 2000, International journal of cancer.

[100]  L. Otvos,et al.  Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells , 2002, The Journal of experimental medicine.

[101]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[102]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[103]  R. Lapointe,et al.  Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments. , 2006, Cancer research.

[104]  A. Anichini,et al.  Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.

[105]  Hailing Lu,et al.  Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1 , 2006, The Journal of Immunology.

[106]  M. Nussenzweig,et al.  Inducing and expanding regulatory T cell populations by foreign antigen , 2005, Nature Immunology.

[107]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[108]  Anne M Evans,et al.  Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy , 2006, Proceedings of the National Academy of Sciences.

[109]  E. Jaffee,et al.  Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. , 1994, Ciba Foundation symposium.

[110]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[111]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[112]  D. Ruiter,et al.  Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. , 1984, Cancer research.

[113]  E. Shevach,et al.  Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[114]  C. Lengauer,et al.  Aneuploidy and cancer , 2004, Nature.

[115]  P. Coulie,et al.  High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens , 2005, The Journal of experimental medicine.

[116]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[117]  S. H. van der Burg,et al.  Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. , 2008, Cancer research.

[118]  S. Rosenberg,et al.  Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[119]  G. V. van Muijen,et al.  Cancer/testis‐associated genes: Identification, expression profile, and putative function , 2003, Journal of cellular physiology.

[120]  N. Maitland,et al.  Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  L. Otvos,et al.  Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones. , 1994, Virology.

[122]  Ulrich Steinhoff,et al.  Link between Organ-specific Antigen Processing by 20S Proteasomes and CD8+ T Cell–mediated Autoimmunity , 2002, The Journal of experimental medicine.

[123]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[124]  A. Anichini,et al.  Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. , 1996, Journal of immunology.

[125]  J. McCluskey,et al.  Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. , 2006, Advances in cancer research.

[126]  Thomas Halder,et al.  Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells , 1998, Cancer Immunology, Immunotherapy.

[127]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[128]  J. Leonard,et al.  Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[130]  S. Blais,et al.  Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes1 , 2008, The Journal of Immunology.

[131]  H. Rammensee,et al.  Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.

[132]  Thomas Kirchner,et al.  Migrating cancer stem cells — an integrated concept of malignant tumour progression , 2005, Nature Reviews Cancer.

[133]  E. Kohn,et al.  Cancer invasion and metastases. , 1990, JAMA.

[134]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 2007, Journal of immunology.

[135]  C. Perreault,et al.  On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens , 1997, European journal of immunology.

[136]  J. Shay,et al.  Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. , 2002, Differentiation; research in biological diversity.

[137]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[138]  J. Herman,et al.  Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.

[139]  T. Schumacher,et al.  Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?1 , 2002, The Journal of Immunology.

[140]  C. Morrissey,et al.  Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. , 2005, Clinical science.

[141]  K. Eichmann,et al.  Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets , 2004, European journal of immunology.

[142]  Liang Cheng,et al.  Clonal origin of lymph node metastases in bladder carcinoma , 2005, Cancer.

[143]  L. Old,et al.  Expression of cancer-testis (CT) antigens in placenta. , 2007, Cancer immunity.

[144]  S. Rosenberg,et al.  T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.

[145]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[146]  H. Schreiber,et al.  Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.

[147]  P. Romero,et al.  Reverse immunology approach for the identification of CD8 T‐cell‐defined antigens: Advantages and hurdles , 2006, Immunology and cell biology.

[148]  E. Caron,et al.  The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.

[149]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[150]  E. V. van Donselaar,et al.  The Melanocytic Protein Melan‐A/MART‐1 Has a Subcellular Localization Distinct from Typical Melanosomal Proteins , 2002, Traffic.

[151]  Emil R Unanue,et al.  The wide diversity and complexity of peptides bound to class II MHC molecules. , 2006, Current opinion in immunology.

[152]  S. Turley,et al.  Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self , 2007, Nature Immunology.

[153]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[154]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[155]  S. Nishikawa,et al.  Molecular characterization of melanocyte stem cells in their niche , 2005, Development.

[156]  V. Brusic,et al.  Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .

[157]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[158]  S. Hirohashi,et al.  FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.

[159]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[160]  M. Bevan,et al.  T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. , 2006, Immunity.

[161]  G. Ossenkoppele,et al.  MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. , 2006, Immunobiology.

[162]  P. Opolon,et al.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. , 2004, The Journal of clinical investigation.

[163]  B. J. Van den Eynde,et al.  Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. , 2001, Current opinion in immunology.

[164]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[165]  M. Vikkula,et al.  New Helicase Gene Antigen Generated by a Point Mutation in a Anti-Melanoma CTL Directed Against an High Frequency of Autologous , 2000 .

[166]  S. H. van der Burg,et al.  Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.

[167]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[168]  V. Engelhard,et al.  Post-translational modifications of naturally processed MHC-binding epitopes. , 2006, Current opinion in immunology.

[169]  J. Crowley,et al.  Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy , 2007, The Journal of experimental medicine.

[170]  R. Turner,et al.  Molecular clonality of in-transit melanoma metastasis. , 2001, The American journal of pathology.

[171]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[172]  N. Bander,et al.  Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. , 1996, The Journal of urology.

[173]  M. Debenedette,et al.  Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. , 2003, The Journal of investigative dermatology.

[174]  A. Sette,et al.  Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 , 2003, The Journal of Immunology.

[175]  G. Pawelec,et al.  Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. , 1997, Cancer research.

[176]  L. Klein,et al.  Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells , 2007, Nature Immunology.

[177]  S. Gendler,et al.  Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas , 2004, The Journal of experimental medicine.

[178]  Ilan Beer,et al.  The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells* , 2006, Molecular & Cellular Proteomics.

[179]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[180]  D. Speiser,et al.  High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.

[181]  E. Sercarz,et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen , 1992, Nature.

[182]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[183]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[184]  M. Kripke,et al.  Stepwise immunologic selection of antigenic variants during tumor growth. , 1986, Journal of immunology.

[185]  B. Monsarrat,et al.  Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation1 , 2006, The Journal of Immunology.

[186]  K. Rock,et al.  Cellular protein is the source of cross-priming antigen in vivo. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[187]  M. J. Tevethia,et al.  Inefficient Cross-Presentation Limits the CD8+ T Cell Response to a Subdominant Tumor Antigen Epitope1 , 2005, The Journal of Immunology.